As the COVID-19 epidemic continues to spread, many countries and regions have called for accelerating the vaccination of booster shots of the COVID-19 vaccine. However, the epidemic is still rebounding, and the epidemic situation in Europe is not optimistic. It can be seen that drug treatment is important in fighting the epidemic, especially the development of specific drugs for COVID-19. Only by finding more ways to treat or prevent COVID-19 can we prevent more patients from developing severe symptoms and reduce deaths.
Selective serotonin reuptake inhibitors (SSRIs) are associated with a reduced relative risk of mortality in COVID-19 patients, according to a study published online on November 15, 2021, in the journal JAMA Network Open.
(Source: Internet)
Tomiko Oskotsky, MD, PhD, from the University of California, San Francisco, and colleagues analyzed electronic health records in a retrospective cohort study to examine the association of SSRIs with COVID-19 patient outcomes. A total of 3,401 adult patients with COVID-19 who took SSRIs between January and September 2020 were matched to a control group of patients who did not receive treatment.
The researchers found that patients taking any SSRI (fluoxetine or fluvoxamine) had a reduced relative risk of mortality compared with controls. Receiving any SSRI other than fluoxetine or fluvoxamine was not associated with a statistically significant risk of death.
"These findings suggest that SSRIs, if proven effective, could serve as a treatment option to reduce mortality in COVID-19 patients," the authors said.
References:
https://www.empr.com/home/news/ssris-linked-to-reduced-relative-risk-for-mortality-in-covid-19/
.jpeg)
